Avantogen’s CEO joins Hawaii Biotech Board of Directors
Avantogen is a significant investor in Hawaii Biotech and intends to purchase additional shares in the company based on proceeds received from Avantogen’s recent $1 million capital raising.
"The Board of Avantogen is firmly convinced that Hawaii Biotech's recombinant DNA manufacturing platform is an excellent investment opportunity, and Avantogen actively seeks to increase its stake in this promising vaccine development company," stated Avantogen Chairman Patrick Elliott.
Hawaii Biotech Inc recently announced initiation of a Phase I West Nile Virus vaccine clinical trial, development of partnerships with PDVI/Bill & Melinda Gates Foundation and the Walter Reed Army Institute of Research, and recruitment of Professor Ian Frazer to the Scientific Advisory Board of Hawaii Biotech Inc. Hawaii Biotech anticipates participating in a Walter Reed sponsored Phase I human clinical trial with their Dengue vaccine candidate early next calendar year.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.